Clinical Trial Update: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of Cixutumumab, Everolimus, and Octreotide acetate in patients with advanced low- to intermediate-grade neuroe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrinoma
• Glucagonoma
• Insulinoma
• Lung Carcinoid Tumor
• Medullary Thyroid Carcinoma
• Merkel Cell Carcinoma
• Pancreatic Neuroendocrine Tumor
• Paraganglioma

Drugs mentioned

• Cixutumumab (Cixutumumab)
• Everolimus (everolimus)
• OCTREOTIDE ACETATE (octreotide acetate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 1 | Status: COMPLETED